Stryker Corporation $SYK Stock Holdings Trimmed by Composition Wealth LLC

Key Points

• Composition Wealth LLC cut its stake in Stryker by 75.2% in Q4, selling 7,173 shares and leaving it with 2,370 shares valued at $833,000.
• Stryker missed quarterly estimates with EPS of $2.60 (vs. $2.98 expected) and revenue of $6.02B (vs. $6.34B expected), but issued FY2026 guidance of 14.900–15.100 EPS (consensus ~14.89).
• Director Ronda E. Stryker sold 250,000 shares at an average $362.92 for about $90.73M, cutting her ownership by 9.23%; insiders now own ~4.6% while institutions hold ~77.1% of the stock.

Composition Wealth LLC cut its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 75.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,370 shares of the medical technology company's stock after selling 7,173 shares during the quarter. Composition Wealth LLC's holdings in Stryker were worth $833,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter valued at $27,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter valued at $30,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker during the 3rd quarter valued at $34,000. Copia Wealth Management increased its position in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after purchasing an additional 69 shares during the period. Finally, WPG Advisers LLC increased its position in shares of Stryker by 156.8% during the 3rd quarter. WPG Advisers LLC now owns 113 shares of the medical technology company's stock valued at $42,000 after purchasing an additional 69 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on SYK. Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday. BTIG Research decreased their target price on Stryker from $397.00 to $379.00 and set a "buy" rating on the stock in a report on Friday. UBS Group decreased their target price on Stryker from $400.00 to $380.00 and set a "neutral" rating on the stock in a report on Tuesday, March 17th. Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday. Finally, Raymond James Financial upgraded Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 target price on the stock in a report on Tuesday, January 6th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $395.48.

Stryker Stock Performance

Shares of NYSE SYK opened at $291.21 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $111.53 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 1.73 and a beta of 0.80. The stock's fifty day simple moving average is $345.67 and its 200 day simple moving average is $356.80. Stryker Corporation has a 52-week low of $290.22 and a 52-week high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 14.89 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Tuesday, March 31st. Stryker's dividend payout ratio (DPR) is 40.74%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm's stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company's stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.